FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023
AFT Pharma reports growth and global expansion
Read More
News
AFT welcomes US FDA approval for sale of Maxigesic IV®
AFT Pharmaceuticals announces the US FDA has approved Maxigesic IV®, the intravenous form of its patented pain relief medicine, for sale in the US, which represents AFT’s second FDA approval within one year.
Read More
AFT Pharmaceuticals to announce half year interim results
AFT Pharmaceuticals announced today that it intends to release on Thursday November 23 2023 its half year interim results for the period ended September 30 2023.
Read More
AFT appoints Andrew Lane as independent director
AFT Pharmaceuticals today announces the appointment of Andrew Lane as an independent non-executive director.
Read More
Retirement of Jon Lamb
Independent director Jon Lamb today retired from the board following his announcement at the ASM.
Read More
AFT Orphan Pharmaceuticals judgment
AFT Pharmaceuticals advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions Limited (PBL) against AFT, and dismissing others.
Read More
AFT launches preservative-free antibacterial eye drop Ocuzo
AFT Pharmaceuticals has opened a new front in its eye drop portfolio, with the introduction of a preservative-free product called Ocuzo for bacterial eye infections.
Read More
New clinical study shows Novaliq NovaTears® +Omega-3 eye drops is significantly effective treatment for dry eye disease.
NovaTears®+Omega-3, an innovative dry eye treatment in-licensed and distributed in Australia and New Zealand by AFT Pharmaceuticals, is a significantly effective treatment for evaporative Dry Eye Disease (DED), a new clinical study1 has found.
Read More
Maxigesic® Oral Liquid gets first regulatory approval
Maxigesic Oral Liquid – a non-opioid analgesic developed for children – achieves first approval in Europe to set up the first global launch and a pathway for further registrations and launches.
Read More
AFT at APP 2021
AFT Pharmaceuticals participate in the Australian Pharmacy Professional (APP) Conference and Trade Exhibition in May 2021.
Read More
AFT extends Maxigesic® IV license in South America
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has licensed Maxigesic IV into Colombia, Peru, Chile, Ecuador, Bolivia, and Uruguay, extending the medicine’s addressable market in Latin America and the Caribbean to 17 countries.
Read More
AFT licenses Maxigesic® IV in the US
AFT Pharmaceuticals announces it has signed an exclusive License and Distribution Agreement with Hikma Pharmaceuticals USA (“Hikma”) for the commercialisation of its Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine, in the United States.
Read More
AFT licenses Pascomer for Europe
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed a new commercialisation and development agreement for its orphan drug Pascomer®
Read More
Maxigesic® IV licensed in eight new European markets
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed an exclusive Maxigesic® IV licensing agreement for eight new European markets.
Read More
AFT confirms demonstration of 24-hour efficacy for Crystawash extend hand sanitiser
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces independent laboratories have found that its new Crystawash Extend Hand Sanitiser
Read More
AFT builds North American momentum
Diversified pharmaceutical company appoints new north American-based director and launches Maxigesic® in Canada.
Read More
Management financial discussion and analysis for the half year to 30 September 2020
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces continued growth in revenue and normalised earnings as it benefits from growth across its portfolio
Read More
Financial results for half year ended 30 September 2020
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces continued growth in revenue and normalised earnings as it benefits from growth across its portfolio.
Read More